Letters to the EditorLikelihood of Positive Urine Screens of THC-COOH After Daily Use of Full-Spectrum Hemp Extracts Varies as a Function of Screening Criterion UsedFerretti, Morgan L. MA*; Vandrey, Ryan PhD†; Irons, Jessica G. PhD‡; Jackson, Heather AA§; Loflin, Mallory J. PhD¶; Hyke, Travis PhD‖; Bonn-Miller, Marcel O. PhD** Author Information *Department of Psychological Science, University of Arkansas, Fayetteville, Arkansas †Department of Psychiatry and Behavioral Science, Johns Hopkins University, Baltimore, Maryland ‡Department of Psychology, James Madison University, Harrisonburg, Virginia §Realm of Caring, Colorado Springs, Colorado ¶Department of Psychiatry, University of California, San Diego, California ‖Sharp Healthcare, San Diego, California **Canopy Growth Corporation, Smith Falls, Ontario, Canada Supported by a grant from the Institute for Research on Cannabinoids (IROC), a 501(c) (3) nonprofit organization supported by individual donations. The authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest: M.L. Ferretti reports personal fees from the Canopy Growth Corporation outside of the submitted work. R. Vandrey reports personal fees from Canopy Growth Corporation, personal fees from MyMD Pharmaceuticals, personal fees from Mira1a Therapeutics, personal fees from Radicle Science Inc, and personal fees from Syqe Medical Ltd, outside the submitted work. J.G. Irons reports a grant and non-financial support from the Canopy Growth Corporation outside the submitted work. M.J. Loflin reports personal fees and nonfinancial support from Jazz Pharmaceuticals. M.O. Bonn-Miller reports personal fees and non-financial support from Canopy Growth Corporation, personal fees and nonfinancial support from AusCann Group Ltd., personal fees and nonfinancial support from the Realm of Caring Foundation, and personal fees and non-financial support from The Lambert Center for the Study of Medicinal Cannabis and Hemp, outside the submitted work. M.O. Bonn-Miller had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of its presentation. Study concept and design: M.O. Bonn-Miller, R. Vandrey, M.J. Loflin; Acquisition, analysis, or interpretation of data: All authors; Drafting of the manuscript: All authors; Critical revision of the manuscript for important intellectual content: All authors; Administrative, technical, or material support: All authors; Study supervision: M.O. Bonn-Miller. Neither the Institute for Research on Cannabinoids (IROC) nor the Canopy Growth Corporation played any role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation or approval of the manuscript; or the decision to submit the manuscript for publication. Therapeutic Drug Monitoring 45(1):p 126-127, February 2023. | DOI: 10.1097/FTD.0000000000001032 Buy Metrics Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.